Zura Bio posted a net loss of $15.993 million in Q2 2025 as the company continued to invest in Phase 2 trials for tibulizumab. R&D and G&A expenses rose significantly year-over-year, while the company maintained a strong cash position.

Zura Bio reported a net loss of $17.4 million for the first quarter of 2025, or $0.19 per share, compared to a net loss of $7.7 million, or $0.02 per share, for the same period in 2024. The company ended the quarter with $170.6 million in cash and cash equivalents, with a cash runway anticipated through 2027. R&D expenses significantly increased to $10.5 million from $3.6 million in the prior year, driven by increased CRO and manufacturing costs for product candidates.

Zura Bio reported a net loss of $22.9 million for Q3 2024, or $0.26 per share, compared to a net loss of $8.3 million, or $0.18 per share, in Q3 2023. The company's cash and cash equivalents totaled $188.2 million as of September 30, 2024, which is anticipated to support operations through 2027. Significant progress was made towards initiating Phase 2 trials for tibulizumab in systemic sclerosis and hidradenitis suppurativa.

Zura Bio reported cash and cash equivalents of $188.2 million as of September 30, 2024. Research and development expenses were $6.0 million, and general and administrative expenses were $13.3 million for the third quarter of 2024. Net loss for the third quarter of 2024 was $22.9 million or $0.26 per share.

Zura Bio reported a net loss of $12.7 million for the second quarter of 2024. The company's cash and cash equivalents were $188.4 million as of June 30, 2024, expected to support operations through 2027. The company is advancing its Phase 2 clinical programs in SSc and HS.

Zura Bio reported a net loss of $7.7 million for Q1 2024. The company's cash and cash equivalents were $89.8 million as of March 31, 2024, and they raised gross proceeds of approximately $112.5 million in an oversubscribed private placement.

Zura Bio reported its full year 2023 financial results, highlighting a cash balance of $99.8 million and the appointment of Robert Lisicki as CEO. The company is focused on advancing its clinical programs, including a Phase 2 trial for tibulizumab.

Zura Bio reported cash and cash equivalents of $112.8 million as of June 30, 2023. R&D expenses were $28.2 million and G&A expenses were $5.7 million for the second quarter ended June 30, 2023.